Abeona Therapeutics: FY25 Earnings Exceed Expectations with GAAP EPS of $1.01

Abeona Therapeutics reported FY25 earnings with a GAAP EPS of $1.01, beating expectations by $0.17. The company benefited from a one-time gain from the sale of its gene therapy program, Zevaskyn. This marks a key inflection point for the company, indicating a shift towards revenue generation. The early revenue from Zevaskyn is a positive sign for Abeona's future prospects.